METTL3 and cancer: A recent study (71) claimed that a high content of METTL3 in CRC patients is not beneficial for the cancer cells’ growth and division, and it also suppresses CRC cell proliferation, migration, and invasion through p38/ERK pathways, suggesting that METTL3 can be considered that a prognostic factor in CRC patients.